ArticleJournal of comparative effectiveness research2024

Real-world clinical outcomes and rationale for initiating abatacept as a first-line biologic for patients with anticitrullinated protein antibody- and rheumatoid factor-positive rheumatoid arthritis.

Alexandrina Balanean et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.